Format

Send to

Choose Destination
Int Rev Immunol. 2012 Apr;31(2):119-32. doi: 10.3109/08830185.2012.664797.

Bruton tyrosine kinase (BTK) and its role in B-cell malignancy.

Author information

1
Pharmacyclics, Inc., Sunnyvale , California , USA.

Erratum in

  • Int Rev Immunol. 2012 Oct;31(5):428.

Abstract

BTK is a kinase that functions downstream of multiple receptors in various hematologic cells. This review focuses on BTK-dependent pathways that are likely to be involved in maintaining the malignant phenotype in B-cell lymphomas and leukemias. Survival of various B-cell malignancies requires BTK-dependent signals from the B-cell antigen receptor. Survival is also dependent on malignant cells homing to and interacting with lymphoid microenvironments, and these interactions are also BTK-dependent due its role in signaling downstream of chemokine and innate immune receptors. The potential for therapeutic targeting of BTK is currently being tested in clinical settings.

PMID:
22449073
DOI:
10.3109/08830185.2012.664797
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center